NCT07173829

Brief Summary

BORDEAUX-GLIO is a prospective, monocentric study which will describe the molecular, immune and metabolic pathways involved in the progression and relapse of glioblastoma, using blood and tumor samples from patients who have undergone surgery for newly diagnosed or recurrent glioblastoma in the center.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
45

participants targeted

Target at P25-P50 for all trials

Timeline
56mo left

Started Sep 2025

Longer than P75 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress13%
Sep 2025Dec 2030

First Submitted

Initial submission to the registry

August 2, 2023

Completed
2.1 years until next milestone

Study Start

First participant enrolled

September 1, 2025

Completed
14 days until next milestone

First Posted

Study publicly available on registry

September 15, 2025

Completed
5.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

September 15, 2025

Status Verified

September 1, 2025

Enrollment Period

5.3 years

First QC Date

August 2, 2023

Last Update Submit

September 10, 2025

Conditions

Glioblastoma

Keywords

Glioblastoma progressionGlioblastoma recurrenceMetabolismLactateMetabolomicTranscriptomicRadiation therapyRadiosensitizerImmunotherapyγδ T lymphocytes

Outcome Measures

Primary Outcomes (3)

  • Molecular mechanism

    Description of the molecular mechanism involved in the progression and recurrence of glioblastoma

    at inclusion (T0)

  • Metabolic mechanism

    Description of the metabolic mechanism involved in the progression and recurrence of glioblastoma.

    at inclusion (T0)

  • Immune mechanism

    Description of the immune mechanism involved in the progression and recurrence of glioblastoma

    at inclusion (T0)

Study Arms (1)

Recruited patient

Glioblastoma patient with indication for neurosurgery

Other: samples

Interventions

samplesOTHER

A 50 ml blood sample will be taken from the patient before the operation, and two 0.3 cm3 tumor samples will be taken during the operation from the resected tumor.

Recruited patient

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery

You may qualify if:

  • Patients of 18 years or older, with highly suspected glioblastoma on neuro-imagery
  • Planned surgical tumor resection,
  • No objection to participate in research
  • Signed genetic consent

You may not qualify if:

  • Patients under guardianship, curatorship or protective supervision
  • Taking immunosuppressants
  • Pregnant or breast-feeding women
  • Patients deprived of their liberty by judicial or administrative decision, or under psychiatric care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

blood Cerebral brain tumor

MeSH Terms

Conditions

Glioblastoma

Interventions

Sampling Studies

Condition Hierarchy (Ancestors)

AstrocytomaGliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue

Intervention Hierarchy (Ancestors)

Epidemiologic Study CharacteristicsEpidemiologic MethodsInvestigative TechniquesHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public Health

Study Officials

  • Julien ENGELHARDT, Dr

    University Hospital, Bordeaux

    PRINCIPAL INVESTIGATOR

  • Mathieu LARROQUETTE, Dr

    University Hospital, Bordeaux

    STUDY CHAIR

  • Guillaume CHOTARD, Dr

    University Hospital, Bordeaux

    STUDY CHAIR

  • Lionel COUZI, Pr

    Bordeaux university Hospital, Bordeaux University

    STUDY CHAIR

  • Andreas BIKFALVI, Pr

    University of Bordeaux

    STUDY CHAIR

  • Charles DUPIN, Dr

    University Hospital, Bordeaux

    STUDY CHAIR

  • Véronique VENDRELY, Pr

    Bordeaux university Hospital, Bordeaux University

    STUDY CHAIR

  • Julie DECHANET-MERVILLE, Dr

    University of Bordeaux

    STUDY CHAIR

  • Thomas DAUBON, Dr

    University of Bordeaux

    STUDY CHAIR

Central Study Contacts

Julien ENGELHARDT, Dr

CONTACT

05 56 79 55 77julien.engelhardt@chu-bordeaux.fr

Olivier BRANCHARD

CONTACT

05 57 82 06 97olivier.branchard@chu-bordeaux.fr

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 2, 2023

First Posted

September 15, 2025

Study Start

September 1, 2025

Primary Completion (Estimated)

December 1, 2030

Study Completion (Estimated)

December 1, 2030

Last Updated

September 15, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share